Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis
Bloch MH, Hannestad J
Molecular psychiatry · 208 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Posiblemente financiado por la industria
- Gobierno
- National Institute of Mental Health
- Gobierno
- National Center for Research Resources
- Gobierno
- NIMH NIH HHS
- Gobierno
- NCRR NIH HHS
- Subvenciones
- National Institute of Mental Health (K23MH091240); National Institute of Mental Health (R25 MH077823); National Institute of Mental Health (1K23MH091240-01); National Center for Research Resources (UL1RR024139)
Según 4 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2011-09-20 · Mol Psychiatry · vol. 17 · número 12 · págs. 1272–1282
- Editorial
- Springer Nature
- Citado
- 293 citas · más que el 89% de estudios similares · 2.4× el promedio de su campo
- Referencias
- 61 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Fatty Acid Research and Health · Treatment of Major Depression · Tryptophan and brain disorders
- Palabras clave
- omega-3 fatty acids, major depressive disorder, depression treatment, eicosapentaenoic acid, docosahexaenoic acid, publication bias, trial heterogeneity, methodological quality, depression severity
- MeSH
- humans, fatty acids, omega-3, dietary supplements, publication bias, randomized controlled trials as topic, major depressive disorder
2 autores
- Michael H. Bloch🇺🇸 · autor de correspondenciaYale University
- Jonas O. Hannestad🇺🇸Yale University
Resumen
El texto original del estudio, en el idioma en que se publicó.
We conducted a meta-analysis of randomized, placebo-controlled trials of omega-3 fatty acid (FA) treatment of major depressive disorder (MDD) in order to determine efficacy and to examine sources of heterogeneity between trials. PubMed (1965-May 2010) was searched for randomized, placebo-controlled trials of omega-3 FAs for MDD. Our primary outcome measure was standardized mean difference in a clinical measure of depression severity. In stratified meta-analysis, we examined the effects of trial duration, trial methodological quality, baseline depression severity, diagnostic indication, dose of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in omega-3 preparations, and whether omega-3 FA was given as monotherapy or augmentation. In 13 randomized, placebo-controlled trials examining the efficacy of omega-3 FAs involving 731 participants, meta-analysis demonstrated no significant benefit of omega-3 FA treatment compared with placebo (standard mean difference (SMD)=0.11, 95% confidence interval (CI): -0.04, 0.26). Meta-analysis demonstrated significant heterogeneity and publication bias. Nearly all evidence of omega-3 benefit was removed after adjusting for publication bias using the trim-and-fill method (SMD=0.01, 95% CI: -0.13, 0.15). Secondary analyses suggested a trend toward increased efficacy of omega-3 FAs in trials of lower methodological quality, trials of shorter duration, trials which utilized completers rather than intention-to-treat analysis, and trials in which study participants had greater baseline depression severity. Current published trials suggest a small, non-significant benefit of omega-3 FAs for major depression. Nearly all of the treatment efficacy observed in the published literature may be attributable to publication bias.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.